Advances in neuroblastoma immunotherapy based on chimeric antigen receptor
10.3969/j.issn.1000-3606.2018.05.017
- VernacularTitle:基于嵌合抗原受体的神经母细胞瘤免疫治疗研究进展
- Author:
Jie ZHAO
1
;
Benshang LI
Author Information
1. 上海交通大学医学院附属上海儿童医学中心血液/肿瘤科 国家卫生和计划委员会儿童血液肿瘤重点实验室
- Keywords:
chimeric antigen receptor;
T cell;
neuroblastoma;
immunotherapy.
- From:
Journal of Clinical Pediatrics
2018;36(5):389-393
- CountryChina
- Language:Chinese
-
Abstract:
Neuroblastoma is the most common extra-cranial malignant tumor in childhood. About 50% of the children have widespread metastatic diseases at initial diagnosis and the outcomes are poor. Chimeric antigen receptor (CAR) is a kind of genetically engineered receptors usually generated by extracellular antigen recognition region, spacer, transmembrane domain and intracellular endodomain. The antigen recognition region joining heavy and light chain variable regions of a monoclonal antibody with a linker to form a single-chain variable fragment (scFv) which can bind to tumor-associated antigens and lead to anti-tumor activity in an MHC-unrestricted manner. In this review, the recent advances and applications of CAR-T cell in neuroblostoma are reviewed and the application-related problems and possible solving strategies are discussed.
